On February 24, 2025, Dr. Ralph Schiess resigned as Interim CEO and Chief Science Officer of Onconetix, and James Sapirstein was appointed as Executive Chairman with a consulting agreement at $400 per hour. Additionally, Andrew Oakley was appointed to the Board, increasing its size to six members, and the date for the 2025 annual meeting was set for June 4, 2025.